FLAURA2
10 Dec 2020
FLAURA2
NCT04035486
A Phase III, Open-label, Randomized Study of Osimertinib With or Without Platinum Plus Pemetrexed Chemo, as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2)
AstraZeneca
Cancer Type | Lung & mesothelioma |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | Both |
Tumour Stream | Advanced Solid Tumors |
Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
Anticipated Start Date | 2019-07-02 |
Anticipated End Date | 2026-03-23 |
Hospital | Lyell McEwin Hospital |
---|---|
Clinical Trial Coordinator | Andy Phay |
andy.phay@sa.gov.au | |
Phone | 08 8282 0833 |
Principal Investigator | Dr Dainik Patel |
Recruitment Status | Recruiting |